Back to search
FDAFDA · Food and drugs·Recall number D-0056-2018

Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01.

Published November 8, 2017 · Recall initiated: October 13, 2017

Summary

FDA records drug Class III recall D-0056-2018, published November 8, 2017 and initiated October 13, 2017. Recalling firm: Sanofi-Aventis U.S. LLC; Status: Terminated; Reported quantity: 422 vials; Lot: Lot #: K5006Y02, Exp 31AUG18. Class III means the product is not likely to cause adverse health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Sanofi-Aventis U.S. LLC
Distributor
Nationwide in the USA
Lot
Lot #: K5006Y02, Exp 31AUG18
Risk classification
Class III
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Clofarabine injection, 20 mg/20 mL, 20 mL Single-Use Vial, Rx only, Mfd by: Teva Pharmachemle, Swensweg 5, Haarlem, The Netherlands; Mfd for: Winthrop U.S., a business of sanofi-aventis U.S. LLC, Bridgewater, NJ 08807; NDC 0955-1746-01. recalled?

Yes. FDA published recall D-0056-2018 on November 8, 2017. Reported hazard: Labeling: Incorrect or Missing Package Insert: authorized generic product was packaged with the incorrect insert for the brand name product Clolar (clofarabine) injection.

What should I do if I have this product?

Voluntary: Firm initiated · Letter